Literature DB >> 28810640

In-hospital and long-term outcomes of congestive heart failure: Predictive value of B-type and amino-terminal pro-B-type natriuretic peptides and their ratio.

Yuxiang Dai1,2, Jun Yang3, Atsutoshi Takagi1, Hakuoh Konishi1, Tetsuro Miyazaki1, Hiroshi Masuda1, Kazunori Shimada1, Katsumi Miyauchi1, Hiroyuki Daida1.   

Abstract

Relative changes in B-type natriuretic peptide (BNP) and amino terminal pro-BNP (NT-proBNP) levels may help to assess the risk of congestive heart failure (CHF). However, whether these levels at the time of admission enable the prediction of outcomes with acute exacerbation remains unknown. The current study determined the abilities of BNP, NT-proBNP and their ratio to predict in-hospital and long-term outcomes of patients with CHF. Patients who were admitted to the cardiac care unit of Juntendo University Hospital (Tokyo, Japan) with acute CHF onset were consecutively enrolled into the present observational study. Serum levels of BNP and NT-proBNP were immediately measured on admission, and other biomarkers and clinical data were also investigated. Of 195 enrolled patients, 16 (8.2%) succumbed to CHF in hospital and 124 (69.3%) reached the endpoint of mortality or readmission following a median follow-up of 14 months. Multiple linear regression analysis revealed body mass index, low density lipoprotein cholesterol, hemoglobin, estimated glomerular filtration rate and C-reactive protein as independent predictors of the NT-proBNP/BNP ratio. BNP, NT-proBNP and their ratio were significantly higher among those who succumbed to CHF than in those who remained alive in hospital (P<0.05). Logistic regression analysis indicated that the ratio was an independent predictor for in-hospital mortality and long-term outcomes. In conclusion, the ratio of NT-proBNP to BNP more effectively predicts in-hospital outcomes than either factor alone and it may also help to predict outcomes among patients with acute exacerbation of HF.

Entities:  

Keywords:  biomarker; brain natriuretic peptides; heart failure; mortality rates

Year:  2017        PMID: 28810640      PMCID: PMC5526175          DOI: 10.3892/etm.2017.4686

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  33 in total

Review 1.  Serum biomarkers for heart failure.

Authors:  Petr Jarolim
Journal:  Cardiovasc Pathol       Date:  2006 May-Jun       Impact factor: 2.185

2.  Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio.

Authors:  Juliana Jensen; Li-Ping Ma; Michael L X Fu; David Svaninger; Per-Arne Lundberg; Ola Hammarsten
Journal:  Clin Res Cardiol       Date:  2010-03-13       Impact factor: 5.460

Review 3.  Use of brain natriuretic Peptide and bioimpedance to guide therapy in heart failure patients.

Authors:  Roberto Valle; Nadia Aspromonte
Journal:  Contrib Nephrol       Date:  2010-04-20       Impact factor: 1.580

4.  Association of plasma B-type natriuretic peptide levels with obesity in a general urban Japanese population: the Suita Study.

Authors:  Takako Sugisawa; Ichiro Kishimoto; Yoshihiro Kokubo; Hisashi Makino; Yoshihiro Miyamoto; Yasunao Yoshimasa
Journal:  Endocr J       Date:  2010-06-01       Impact factor: 2.349

Review 5.  Evaluation and management of the acutely dyspneic patient: the role of biomarkers.

Authors:  Alex Harrison; Stanley Amundson
Journal:  Am J Emerg Med       Date:  2005-05       Impact factor: 2.469

Review 6.  Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure.

Authors:  A Palazzuoli; M Gallotta; I Quatrini; R Nuti
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

7.  Atrial natriuretic factor: a hormone produced by the heart.

Authors:  A J de Bold
Journal:  Science       Date:  1985-11-15       Impact factor: 47.728

8.  Plasma NT-proBNP as a more reliable biomarker of endogenous cardiac natriuretic peptides than BNP during carperitide infusion.

Authors:  Keizo Nishiyama; Takayoshi Tsutamoto; Toshinari Tanaka; Masanori Fujii; Takashi Yamamoto; Masayuki Yamaji; Minoru Horie
Journal:  Int Heart J       Date:  2009-03       Impact factor: 1.862

Review 9.  Cardiovascular disease in patients with chronic renal impairment: role of natriuretic peptides.

Authors:  Marc Vanderheyden; Jozef Bartunek; Gerasimos Filippatos; Marc Goethals; Bruno Van Vlem; Alan Maisel
Journal:  Congest Heart Fail       Date:  2008 Jul-Aug

Review 10.  NT-proBNP in heart failure: therapy decisions and monitoring.

Authors:  Mark Richards; Richard W Troughton
Journal:  Eur J Heart Fail       Date:  2004-03-15       Impact factor: 15.534

View more
  3 in total

1.  Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis.

Authors:  Francesco Spannella; Federico Giulietti; Marica Bordicchia; John C Burnett; Riccardo Sarzani
Journal:  Sci Rep       Date:  2019-12-16       Impact factor: 4.379

2.  Influencing factors of NT-proBNP level inheart failure patients with different cardiacfunctions and correlation with prognosis.

Authors:  Liang Xu; Yanchun Chen; Yanni Ji; Song Yang
Journal:  Exp Ther Med       Date:  2018-05-02       Impact factor: 2.447

3.  Ghrelin Alleviates Angiotensin II-Induced H9c2 Apoptosis: Impact of the miR-208 Family.

Authors:  Xiaotong Wang; Chunyan Yang; Xueyan Liu; Ping Yang
Journal:  Med Sci Monit       Date:  2018-09-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.